Rapport Therapeutics Reports Q2 2026 Results

What Happened
Rapport Therapeutics, Inc. announced its financial results and business highlights for the quarter ended June 30, 2026. The company furnished a press release with those results as Exhibit 99.1 to a Form 8-K filed on August 5, 2026. The filing was signed by Troy Ignelzi, Chief Financial Officer.

Key Details

• Filing date: August 5, 2026 (Form 8-K).
• Reporting item: Item 2.02 — Results of Operations and Financial Condition (quarter ended June 30, 2026).
• Exhibit: 99.1 — Press release issued August 5, 2026, containing the announced results and business highlights.
• Signature: Form 8-K signed by Troy Ignelzi, Chief Financial Officer.

Why It Matters
This 8-K signals that Rapport has issued its latest quarterly results and operational update; investors should review the attached press release (Exhibit 99.1) or the company’s investor relations page for revenue, earnings, and other financial metrics. Timely disclosure via an 8-K helps shareholders and analysts assess recent performance and any near-term impacts on guidance, cash position, or ongoing programs.